Medtronic Marquis DR
This article was originally published in The Gray Sheet
Executive Summary
Dual-chamber implantable cardioverter defibrillator receives FDA market go-ahead, offering faster charge times, improved longevity and patient alerts compared to previous GEM ICD family offerings, the firm claims. The 36 cc device delivers 30 joules, a charge time of 7.5 seconds and lasts 7-8 years...
You may also be interested in...
Medtronic Marquis VR
Single-chamber version of the Marquis implantable cardioverter defibrillator launches Dec. 18 following FDA approval. The market-leading dual-chamber version (DR) was approved in March (1"The Gray Sheet" March 4, 2002, In Brief). The 75 g 36 cc VR features the highly specific Wavelet detectionalgorithm to distinguish significant arrhythmias from benign fluctuations in the heart's rhythm, Medtronic explains in a release...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.